Skip to main content

Table 1 Patients characteristics of the overall cohort and the sedated versus non-sedated patients; missing data range <1

From: Sedation at the end of life - a nation-wide study in palliative care units in Austria

  Overall cohort (N = 2414) Sedated patients (n = 502, 21 %) Non-sedated patients (n = 1912, 79 %) p-value Corrected p-value effect size
Age in years in median (IQR) 73 (64–82) 67 (56–75) 74 (65–83) ≤0.001* ≤0.001* r = 0.220
Time between admission and death in days in median (IQR) 9 (4 – 20) 10 (5–19) 9 (4–22) 0.491 0.491 -
  n % n % n %    
Sex        0.014* 0.070 φ = 0.051
 Female 1251 52 % 236 47 % 1015 53 %  
 Male 1158 48 % 266 53 % 892 47 %  
Oncological disease 2027 84 % 461 92 % 1566 82 % ≤0.001* ≤0.001* φ = 0.107
Other diseases 372 15 % 40 8 % 332 17 %    
Type of palliative care        ≤0.001* ≤0.001* φ = 0.175
 Hospital based 1930 80 % 470 94 % 1460 76 %  
 Mobile 484 20 % 32 6 % 452 24 %  
Co-medication in the last three days of life          
 Opioids pain medication 2213 92 % 484 96 % 1729 90 % ≤0.001* ≤0.001* φ = 0.100
 Non-opioid pain medication 1271 53 % 240 48 % 1031 54 % 0.032* 0.128 φ = 0.044
 I.v. hydration 1018 42 % 242 48 % 776 41 % 0.001* 0.006* φ = 0.077
 Artificial nutrition 624 26 % 114 23 % 510 27 % ≤0.001* ≤0.001* φ = 0.099
 Antibiotic treatment 404 17 % 96 19 % 308 16 % 0.088 0.176  
 DVTP medication 571 24 % 133 27 % 438 23 % 0.071 0.213  
  1. Abbreviations: N number, IQR interquartile range, I.v. intravenous, DVTP deep venous thrombosis prophylaxis